Goodwin Advises Frazier Life Sciences Acquisition Corp. II on Its $75 Million Initial Public Offering
The Life Sciences team advised Frazier Life Sciences Acquisition Corp. II on the closing of its $75 million initial public offering of 7,500,000 Class A ordinary shares at a price of $10.00 per share. The Class A ordinary shares began trading on the Nasdaq Capital Market on October 14, 2026, and are listed under the ticker symbol “FLSC.”
Frazier Life Sciences Acquisition Corp. II, a special purpose acquisition company, was formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. Frazier Life Sciences Acquisition Corp. II is sponsored by Frazier Life Sciences, a longstanding biotech investment firm with venture and public strategies partnering with and building companies developing novel therapeutics.
The Goodwin team was led by Jocelyn Arel, Jeff Letalien, Kathryn Clerici, Lilly Weitz, Dan Karelitz, Matt Dunay, and Keerthi Adusumilli.
For more information on the deal, please read the press release.